Trop-2 Protein As a Therapeutic Target: A Focused Review on Trop-2-based Antibody-drug Conjugates and Their Predictive Biomarkers

Overview

Journal Bosn J Basic Med Sci

Specialty General Medicine

Date 2021 Jun 28

PMID 34181512

Citations 16

Authors

Semir Vranic

Zoran Gatalica

Affiliations

Soon will be listed here.

Abstract

Antibody-drug conjugates (ADCs) represent a new class of highly potent antineoplastic drugs built by attaching a small molecule of an anticancer drug (payload) or another therapeutic agent to an antibody recognizing an epitope on the targeted cells. Trophoblast cell-surface antigen-2 (Trop-2) was originally described in trophoblasts and fetal tissues, but subsequently, its overexpression has been demonstrated in various solid malignancies. Sacituzumab govitecan, a conjugate of anti-Trop-2 antibody and SN-38 payload (an active metabolite of irinotecan), is the first in the class that has been clinically validated and approved by the Food and Drug Administration for the treatment of metastatic triple-negative breast (2020) and urothelial carcinomas (2021). In the current review, we summarize and critically appraise the most recent advances with Sacituzumab govitecan, emphasizing the predictive biomarker analysis.

Citing Articles

Current Status and Future Prospects of TROP-2 ADCs in Lung Cancer Treatment.

Li M, Jin M, Peng H, Wang H, Shen Q, Zhang L Drug Des Devel Ther. 2024; 18:5005-5021.

PMID: 39525044 PMC: 11550919. DOI: 10.2147/DDDT.S489234.

Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors.

Wang J, Tong Z, Tan Y, Shi Y, Wu Y, Zhou Q Cell Rep Med. 2024; 5(9):101707.

PMID: 39216478 PMC: 11524954. DOI: 10.1016/j.xcrm.2024.101707.

Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer.

Sato S, Shoji T, Jo A, Otsuka H, Abe M, Tatsuki S Cancers (Basel). 2024; 16(14).

PMID: 39061184 PMC: 11275051. DOI: 10.3390/cancers16142545.

Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy.

Vranic S, Gatalica Z Biomol Biomed. 2024; 24(4):673-675.

PMID: 38656302 PMC: 11293230. DOI: 10.17305/bb.2024.10641.

A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers.

Zhou D, Zhai X, Zhang L, Xie Z, Wang Y, Zhen Y NPJ Precis Oncol. 2024; 8(1):94.

PMID: 38654141 PMC: 11039471. DOI: 10.1038/s41698-024-00584-z.

References

Vidula N, Ellisen L, Bardia A . Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative. J Natl Compr Canc Netw. 2020; :1-9. DOI: 10.6004/jnccn.2020.7600. View

Goldenberg D, Stein R, Sharkey R . The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018; 9(48):28989-29006. PMC: 6034748. DOI: 10.18632/oncotarget.25615. View

Perrone E, Lopez S, Zeybek B, Bellone S, Bonazzoli E, Pelligra S . Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. Front Oncol. 2020; 10:118. PMC: 7028697. DOI: 10.3389/fonc.2020.00118. View

Rudolf E, Kralova V, Rudolf K, John S . The role of p38 in irinotecan-induced DNA damage and apoptosis of colon cancer cells. Mutat Res. 2013; 741-742:27-34. DOI: 10.1016/j.mrfmmm.2013.02.002. View

Millis S, Bryant D, Basu G, Bender R, Vranic S, Gatalica Z . Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. Clin Genitourin Cancer. 2014; 13(1):e37-49. DOI: 10.1016/j.clgc.2014.07.010. View

Zaman S, Jadid H, Denson A, Gray J . Targeting Trop-2 in solid tumors: future prospects. Onco Targets Ther. 2019; 12:1781-1790. PMC: 6402435. DOI: 10.2147/OTT.S162447. View

Simms A, Jacob R, Cohen C, Siddiqui M . TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility. Diagn Cytopathol. 2015; 44(1):26-31. DOI: 10.1002/dc.23382. View

Heestand G, Schwaederle M, Gatalica Z, Arguello D, Kurzrock R . Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. Eur J Cancer. 2017; 83:80-87. PMC: 5613945. DOI: 10.1016/j.ejca.2017.06.019. View

Cardillo T, Sharkey R, Rossi D, Arrojo R, Mostafa A, Goldenberg D . Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in -wild-type Triple-Negative Breast Cancer. Clin Cancer Res. 2017; 23(13):3405-3415. DOI: 10.1158/1078-0432.CCR-16-2401. View

10.

Stepan L, Trueblood E, Hale K, Babcook J, Borges L, Sutherland C . Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011; 59(7):701-10. PMC: 3201164. DOI: 10.1369/0022155411410430. View

11.

Rugo H, Bardia A, Tolaney S, Arteaga C, Cortes J, Sohn J . TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. Future Oncol. 2020; 16(12):705-715. DOI: 10.2217/fon-2020-0163. View

12.

Avellini C, Licini C, Lazzarini R, Gesuita R, Guerra E, Tossetta G . The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. Oncotarget. 2017; 8(35):58642-58653. PMC: 5601681. DOI: 10.18632/oncotarget.17407. View

13.

Zhao W, Kuai X, Zhou X, Jia L, Wang J, Yang X . Trop2 is a potential biomarker for the promotion of EMT in human breast cancer. Oncol Rep. 2018; 40(2):759-766. DOI: 10.3892/or.2018.6496. View

14.

Goldenberg D, Sharkey R . Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019; 11(6):987-995. PMC: 6748572. DOI: 10.1080/19420862.2019.1632115. View

15.

Wolber P, Nachtsheim L, Hoffmann F, Klussmann J, Meyer M, von Eggeling F . Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target. Head Neck Pathol. 2021; 15(4):1147-1155. PMC: 8633075. DOI: 10.1007/s12105-021-01325-5. View

16.

Chau C, Steeg P, Figg W . Antibody-drug conjugates for cancer. Lancet. 2019; 394(10200):793-804. DOI: 10.1016/S0140-6736(19)31774-X. View

17.

Han C, Perrone E, Zeybek B, Bellone S, Tymon-Rosario J, Altwerger G . In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. Gynecol Oncol. 2019; 156(2):430-438. DOI: 10.1016/j.ygyno.2019.11.018. View

18.

Guerra E, Trerotola M, Aloisi A, Tripaldi R, Vacca G, La Sorda R . The Trop-2 signalling network in cancer growth. Oncogene. 2012; 32(12):1594-600. DOI: 10.1038/onc.2012.151. View

19.

Shvartsur A, Bonavida B . Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015; 6(3-4):84-105. PMC: 4426947. DOI: 10.18632/genesandcancer.40. View

20.

Nejadmoghaddam M, Minai-Tehrani A, Ghahremanzadeh R, Mahmoudi M, Dinarvand R, Zarnani A . Antibody-Drug Conjugates: Possibilities and Challenges. Avicenna J Med Biotechnol. 2019; 11(1):3-23. PMC: 6359697. View